Little Boy Fighting Cancer Desperately needs Experimental Treatment as a Last Hope
Youngest patient to receive DeltaRex-G
Dr. Gordon examines Kian at the Sarcoma Oncology Center
The Aveni Foundation mission is to expedite development of gene-targeted technologies for cancer and COVID-19, an unmet medical need.
Youngest Patient to Receive DeltaRex-G, an Innovative Gene Targeted Cancer Therapy
This Medicine has passed phase 2 trials and is approved by the FDA for compassionate use. Unlike chemotherapy, there are no major side effects with this drug. Kian has received several doses and is showing improvement. He needs many months more of the medicine, but unfortunately the current supply of DeltaRex-G is running out.
DeltaRex-G is supplied by the Aveni Foundation, a public charity founded by Dr. Gordon, that raises money through generous benefactors to make the medicine. It is not available through drug or insurance companies. Kian’s family started a GO FUND ME campaign and so far have raised over $60,000. They need to raise $500,000 to make another batch of Delta Rex-G. This new supply will not ONLY help Kian, but dozens of other cancer patients, including those battling pancreatic, breast and other sarcomas. Dr. Gordon can share stories of other late stage patients who are long term survivors after being treated with Delta Rex-G.
WHERE: Cancer Center of Southern California (Sarcoma Oncology Center), 2811 Wilshire Boulevard #414 Santa Monica CA 90403
WHEN: Wednesday September 22. 11am and Friday September 24, 11am.
Kian will be receiving his final doses. There will be an opportunity for b-roll along with interviews with Kian, his Mom and Dr. Gordon.
Thank you for considering sharing the story of this brave boy. His story will raise awareness about the successes of Delta Rex-G and how it may revolutionize future cancer treatment.
https://gofund.me/183d1940
Erlinda Maria Gordon
Aveni Foundation
+1 818-726-3278
egordon@avenifoundation.org
Visit us on social media:
Facebook
Twitter
LinkedIn
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
